Novartis has restructured its Pharmaceuticals Division by creating two business units—Novartis Pharmaceuticals and Novartis Oncology. Both units will form the Innovative Medicines Division. Paul Hudson will be appointed chief executive officer, Novartis Pharmaceuticals, and Bruno Strigini will become chief executive officer, Novartis Oncology. Both will report directly to Joseph Jimenez, chief executive officer, Novartis. With these changes, David Epstein, currently division head and chief execu...